



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

Date: 13th August, 2026

To,
The Deputy Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400001.

Sub: Outcome of Board Meeting held on Thursday, 13th August, 2026 pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Ref: Scrip Code: 586565

Scrip Id: NOVELIX

Respected Sir/ Madam,

This is to inform that Board of Directors of the Company in their meeting held on Thursday, 13th August, 2026 at the registered office of the company i.e. H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029, which commenced at 5:00 P.M. has Considered and Approved the Standalone Unaudited Financial Results of the company for the quarter ended 30th June, 2026 along with the Limited Review Report thereon.

The Meeting was concluded at 05:35 P.M. with the vote of thanks.

We request you to take the aforesaid information on record for dissemination through your website.

Thanking you,

Yours Faithfully,

For Novelix Pharmaceuticals Limited

Venkateshwarlu Pulluru
(Whole-time director)
DIN: 02076871

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com



CVS Balachandra Rao & Co.,
Chartered Accountants

Limited Review Report on Standalone Unaudited Quarterly Financial Results of Novelix Pharmaceuticals Limited (Formerly Trimurthi Limited) pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors
Novelix Pharmaceuticals Limited
(Formerly known as Trimurthi Limited)

We have reviewed the accompanying statement of Standalone unaudited quarterly financial results of **Novelix Pharmaceuticals Limited (Formerly known as Trimurthi Limited)** for the quarter ended on 30th June, 2026, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, (the Regulation) as amended, (the "Listing Regulations").


This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For CVS Balachandra Rao & Co.,
Chartered Accountants

ICAI Firm Regd No: 0075078


CVS Balachandra Rao
Partner



Membership Number: 204580

UDIN: 26204580HBVZEG4518

Date: 13/08/2025

Place: Hyderabad

D.No: 3-6-108/1, Flat No: 203, Sanatana Eternal, Street No: 19, Himayat Nagar, Hyderabad - 500 029, Telangana

☎ 9849035315, 9010624455

✉ cacsvala@gmail.com, cvsvala67@gmail.com, 🌐 Website : www.cabrc.in

Branch Office : D.No. 11-33-7B, 2nd Floor, Tatakulavari Street, Samarang Chowk, Vijayawada - 520 001, A.P.

H.No. 16-2/20/3, Sainiranjion Colony, Dogguvanipalem, Pendurthy - 531 173, Vishakapatnam, A.P.



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314101036)

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE 2026

S. No	Particulars	Rs. (In Lakhs)			
		3 Months ended	Preceding 3 Months ended	Corresponding 3 Months ended in previous year	Year ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
		Unaudited	Audited	Unaudited	Audited
1	Revenue				
	a) From operations	3,691.39	2,519.36	2,235.12	13,230.62
	b) Other Income	0.12	(0.00)	-	3.26
	Total Revenue	3,691.51	2,519.36	2,235.12	13,233.88
2	Expenses				
	(a) Cost of Material Consumed	-	-	-	-
	(b) Purchases of stock-in-trade	3,193.39	3,284.31	2,249.50	14,030.37
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	292.95	(994.40)	(71.64)	(1,358.89)
	(d) Employees Benefits expenses	19.66	23.90	16.46	71.83
	(e) Finance Cost	11.54	-	-	-
	(f) Depreciation amortization expenses	7.00	4.61	1.10	10.11
	(g) Other Expenses	55.44	77.65	22.76	140.03
	Total Expenses	3,579.98	2,396.07	2,218.18	12,893.45
3	Profit from ordinary activities before exceptional Items (1 - 2)	111.53	123.29	16.94	340.43
4	Exceptional Items - Income/ (Expenses)	-	-	-	-
5	Profit from ordinary activities before tax (3 - 4)	111.53	123.29	16.94	340.43
6	Tax Expenses				
	(a) Current Tax	25.64	32.65	3.54	83.02
	(b) Deferred Tax	(32.00)	(0.56)	2.70	1.75
7	Profit/(Loss) for the period (5 - 6)	117.89	91.19	10.70	255.66
8	A (i) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-



Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6TH Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314101036)

	B (i) Items that will not be reclassified to profit or loss (net of tax)				
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-
9	Total Comprehensive Income, net of tax (7 + 8)	117.89	91.19	10.70	255.66
10	Paid up equity share capital (Face Value of Rs.10/- each)	2,389.50	2108.50	2,389.50	2108.50
11	Earning per share of Rs.10/- each) not annualised				
	(a) Basic	0.49	0.43	0.09	1.21
	(b) Diluted	0.49	0.32	0.11	1.75
NOTES:					
1	The above Unaudited Financial Results of the company for the quarter ended June 30 th 2026 have been reviewed by the Audit Committee and on its recommendation, have been approved by the Board of Directors at its meeting held on August 13, 2026.				
2	The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs).				
3	Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.				
4	These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016				
5	The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.				
6	The results of the Company for the quarter ended June 30, 2026 are available on the Company's website www.novelixpharma.com and on the BSE Limited website - www.bseindia.com				
7	The company has no Subsidiary, Associate or Joint Venture company(ies), as on June 30, 2026				

For Novelix Pharmaceuticals Limited

Venka



Venkateshwarlu Pulluru
(Whole-time director)

DIN: 02076871

Date: 13/08/2026

Place: Hyderabad

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com